Trial Profile
A Phase 1, Open-label, Randomized, Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2020
Price :
$35
*
At a glance
- Drugs Lumicitabine (Primary) ; Lansoprazole; Ranitidine
- Indications Metapneumovirus infections; Parainfluenza virus infections; Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 19 Jul 2018 Status changed from recruiting to discontinued.
- 21 Mar 2018 New trial record